<DOC>
	<DOCNO>NCT00152178</DOCNO>
	<brief_summary>This control study design evaluate relapse-free survival UFT + TAM compare CMF + TAM . Patients randomly assign receive either CMF + TAM UFT + TAM within 6 week surgery . To assess treatment efficacy , data recurrence survival collect 5 year surgery . To evaluate safety , data adverse event collect treatment . Patients'quality life assess mean questionnaire .</brief_summary>
	<brief_title>The Comparative Trial UFT + TAM With CMF + TAM Adjuvant Therapy Breast Cancer ( CUBC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Age 20 65 Hematopoietic WBC ≥ 4,000/mm^3 Platelet ≥ 100,000/mm^3 Hemoglobin ≥ 11.0 g/dL Hepatic AST ALT ≤ 40 U/L Total bilirubin ≤ 1.5 mg/dL Renal BUN ≤ 25 mg/dL Creatinine ≤ 1.5 mg/dL</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>